Dyslipidemia refers to abnormalities in the composition, concentration, or size of lipids and lipoproteins in the circulation, and it is a key modifiable risk factor for cardiovascular (CV) disease. With respect to lipid-modifying therapies, the greatest commercial success has come via agents reducing low-density lipoprotein (LDL)-cholesterol, but research and development focusing on triglycerides, high-density lipoprotein (HDL)-cholesterol, and other novel biomarkers is ongoing, with the aim of ultimately providing CV benefits. During the 2017-2027 forecast period, the dyslipidemia market is expected to have two distinct phases: 1) early contraction owing largely to the genericization of the dominant statin class, and 2) marked growth due to the emergence of novel therapies, including Amgen’s Repatha, Sanofi/Regeneron Pharmaceuticals’ Praluent, Amarin’s Vascepa, Kowa Pharmaceuticals’ Parmodia (pemafibrate), The Medicines Company/Alnylam Pharmaceuticals’ inclisiran, Esperion Therapeutics’ bempedoic acid, and AstraZeneca’s Epanova.
- What impact will the genericization of AstraZeneca’s Crestor (rosuvastatin)and Merck’s Zetia/Ezetrol (ezetimibe) and Vytorin/Inegy (ezetimibe/simvastatin) have on the dyslipidemia market?
- How will CV outcomes data for the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and omega-3 fatty acid compounds affect the market?
- How will the anticipated launch of Esperion Therapeutics’ orally administered bempedoic acid affect the use of the injectable PCSK9 inhibitors? Which products will achieve the greatest use and why?
- What impact will the anticipated launch of Kowa’s Parmodia and AstraZeneca’s Epanova have on the management of hypertriglyceridemia?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.